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Abstract: Magnesium gluconate is a potent antioxidant and widely used for the prevention and treatment of hypomagnesia. 
The current research was aimed to investigate the impact of The Trivedi Effect® - Energy of Consciousness Healing Treatment 
on magnesium gluconate for the change in the physicochemical, structural, thermal and behavioral properties using PXRD, 
PSD, FT-IR, UV-vis spectroscopy, TGA, and DSC analysis. Magnesium gluconate was divided into two parts – one part was 
control without any Biofield Energy Treatment, while another part was treated with The Trivedi Effect® - Energy of 
Consciousness Healing Treatment remotely by seven renowned Biofield Energy Healers and defined as The Trivedi Effect® 
Treated sample. The PXRD analysis exhibited that the crystallite size of the treated sample was remarkably changed from -
24.96% to 99.98% compared with the control sample. The average crystallite size was significantly increased by 7.79% in the 
treated sample compared with the control sample. PSD analysis revealed that the particle sizes in The Trivedi Effect® Treated 
sample at d10, d50 and d90 values were decreased by 5.36%, 11.35% and 0.90%, respectively compared with the control sample. 
The surface area analysis revealed that surface area of the Biofield Energy Treated sample was significantly increased by 
7.48% compared with the control sample. The FT-IR and UV-vis analysis showed that structure of the magnesium gluconate 
remained the same in both the treated and control samples. The TGA analysis revealed four steps thermal degradation of both 
the samples and the total weight loss of Biofield Energy Treated sample was increased by 0.12% compared with the control 
sample. The DSC analysis demonstrated that the melting temperature of the Biofield Energy Treated sample (171.29°C) was 
increased by 0.18% compared with the control sample (170.99°C). The latent heat of fusion was significantly increased by 
27.09% in the treated sample compared with the control sample. The current study revealed that The Trivedi Effect® - Energy 
of Consciousness Healing Treatment (Biofield Energy Healing Treatment) might lead to a new polymorphic form of 
magnesium gluconate, which would be more soluble, bioavailable, and thermally stable compared with the untreated 
compound. The Biofield Treated sample could be more stable during manufacturing, delivery or storage conditions than the 
untreated sample. Hence, The Trivedi Effect® Treated magnesium gluconate would be very useful to design better nutraceutical 
and/or pharmaceutical formulations that might offer better therapeutic responses against inflammatory diseases, immunological 
disorders, stress, aging, and other chronic infections. 
Keywords: Biofield Energy Healing Treatment, Consciousness Energy Healers, The Trivedi Effect®,  
Magnesium Gluconate, PXRD, Particle Size, TGA, DSC 
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1. Introduction 
Magnesium gluconate (MgC12H22O14) is an organometallic 
salt of magnesium with gluconic acid and is very useful 
nutraceutical/pharmaceutical as a source of magnesium [1]. 
Magnesium is a crucial cofactor of several RNA and DNA 
processing enzymes and also for those enzymes using AMP, 
ADP, or ATP as substrates [2]. Magnesium gluconate has 
been reported as a potent antioxidant agent than other 
magnesium salts [3]. Magnesium gluconate has shown the 
highest level of bioavailability than any other magnesium salt 
and is more physiologically acceptable salt among the 
magnesium salts such as chloride, sulfate, citrate, lactate, 
aspartate, etc. [4, 5]. Hence, Magnesium gluconate is 
recommended as a better salt for magnesium 
supplementation [6]. Magnesium gluconate has been found to 
be very useful for the prevention and treatment of several 
diseases, such as diabetes mellitus, allergies, septic shock, 
inflammatory diseases, immunological disorders, asthma, 
arrhythmias, acute myocardial infarction, gestational 
hypertension, preeclampsia, eclampsia, hearing loss etc. [3, 
4, 7-12]. It can be used intravenously in the treatment of 
ischemia/reperfusion injury due to oxidative stress in order to 
block free radical flow [13]. This organometallic salt can be 
used in a skin-tightening cosmetic composition [14]. It is also 
used as an oral tocolytic agent in women, whose labor is 
arrested initially with intravenous therapy by acting on non-
selective β-receptor [15]. In this point of view, a novel 
proprietary herbomineral formulation was designed as a 
nutraceutical supplement, which can be used for the 
prevention and treatment of various human disorders. 
Magnesium gluconate is one of the components in this novel 
proprietary herbomineral formulation as the source of 
magnesium. 
Since ancient times, many different cultures, religions, and 
systems of belief have recognized a living force that 
preserves and inhabits every living organism. This force is 
the source of ‘life’ and has been called various names, such 
as prana by the Hindus, qi or chi by the Chinese, and ki by 
the Japanese. This is believed to co-relate with the soul, spirit 
and mind. This hypothetical vital force has been scientifically 
evaluated and is now considered the Bioenergetics Field. The 
Biofield Energy is a dynamic electromagnetic field 
surrounding the human body, resulting from the continuous 
emission of low-level light, heat, and acoustical energy from 
the body. Biofield Energy is infinite, paradimensional and 
can freely flow between the human and environment [19, 
20]. Thus, a human has the ability to harness energy from the 
ionosphere of the earth, the “universal energy field”, and 
transmit it to any living organism(s) or nonliving object(s) 
around the globe. The object or recipient always receives the 
energy and responds in a useful way. This process is known 
as The Trivedi Effect® - Biofield Energy Healing Treatment 
[21]. Biofield (Putative Energy Field) based Energy 
Therapies are used worldwide to promote health and healing. 
The National Center of Complementary and Integrative 
Health (NCCIH) has recognized and accepted Biofield 
Energy Healing as a Complementary and Alternative 
Medicine (CAM) health care approach in addition to other 
therapies, medicines and practices such as natural products, 
deep breathing, yoga, Tai Chi, Qi Gong, 
chiropractic/osteopathic manipulation, meditation, massage, 
special diets, homeopathy, progressive relaxation, guided 
imagery, acupressure, acupuncture, relaxation techniques, 
hypnotherapy, healing touch, movement therapy, pilates, 
rolfing structural integration, mindfulness, Ayurvedic 
medicine, traditional Chinese herbs and medicines, 
naturopathy, essential oils, aromatherapy, Reiki, cranial 
sacral therapy and applied prayer (as is common in all 
religions, like Christianity, Hinduism, Buddhism and 
Judaism) [22]. Biofield Energy Healing Treatment (The 
Trivedi Effect®) has been published in numerous peer-
reviewed science journals due to its significant impacts in the 
science fields of biotechnology [23, 24], genetics [25, 26], 
cancer [27, 28], microbiology [29, 30], materials science [31, 
32], agriculture [33, 34], pharmaceuticals [35, 36], 
nutraceuticals [37, 38], organic compounds [39, 40]. These 
publications reported that Biofield Energy Treatment (The 
Trivedi Effect®) has the significant capability to transform 
the physical, structural, chemical, thermal and behavioral 
properties of non-living substances as well as modulate the 
efficacy of various living substance. Although magnesium 
gluconate displays the highest bioavailability and moderate 
solubility in water in comparison to other magnesium salts, 
humans still face problems in achieving their daily 
requirements of magnesium [41]. The physical and chemical 
properties such as particle size, crystalline structure, 
crystallite size, surface area, etc. of a pharmaceutical have a 
direct influence on the absorption, dissolution, and 
bioavailability of the drug [42]. The stability of a solid drug 
with respect to the atmospheric conditions is very important 
to the pharmaceutical industry during processing, 
formulation, storage, and packaging in order to achieve better 
therapeutic efficacy [43]. Biofield Energy Treatment (The 
Trivedi Effect®) has been reported to change the particle size, 
specific surface area, crystalline, chemical and thermal 
behavior of an atom/ion through possible mediation of 
neutrinos [44]. Scientific literature mentions that powder X-
ray diffraction (PXRD), particle size distribution analysis 
(PSD), Fourier transform infrared (FT-IR) spectrometry, 
ultraviolet-visible (UV-vis) spectroscopy, thermogravimetric 
analysis (TGA), and differential scanning calorimetry (DSC) 
analysis play an vital role for solving various problems 
encountered in industries for the pharmaceutical / 
nutraceutical formulation and developments [45]. By 
considering these aspects, the physicochemical, structural, 
thermal, and behavioral properties of the Biofield Energy 
Treated and untreated magnesium gluconate were studied 
using various analytical techniques including PXRD, PSD, 
FT-IR, UV-vis spectroscopy, TGA, and DSC. 
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2. Materials and Methods 
2.1. Chemicals and Reagents 
Magnesium gluconate hydrate was procured from Tokyo 
Chemical Industry Co., Ltd. (TCI), Japan. All other 
chemicals used in the experiment were of analytical grade 
available in India.  
2.2. Energy of Consciousness Treatment Strategies 
Magnesium gluconate was one of the components of the 
new proprietary herbomineral formulation, which was 
developed by our research team and was used per se as the 
test compound for the current study. The test compound was 
divided into two parts, one part of the test compound did not 
receive any sort of treatment and was defined as the untreated 
or control magnesium gluconate sample. The second part of 
the test compound was denoted as the Biofield Energy 
Treated or The Trivedi Effect® Treated sample. The treated 
magnesium gluconate was subjected to The Trivedi Effect® - 
Energy of Consciousness Healing Treatment (Biofield 
Energy Healing Treatment) by the group of seven renowned 
Biofield Energy Healers remotely. All seven Biofield Energy 
Healers were remotely located in the U.S.A., while the test 
compound was located in the research laboratory of GVK 
Biosciences Pvt. Ltd., Hyderabad, India. The Trivedi Effect® 
- Energy of Consciousness Healing Treatment (Biofield 
Energy Healing Treatment) was provided for 5 minutes 
through the Healer’s Unique Energy Transmission process 
remotely to the test compound, which was kept under 
laboratory conditions. None of the Biofield Energy Healers 
in this study visited the laboratory in person, nor had any 
contact with the compounds. Similarly, the control compound 
was subjected to “sham” healer for 5 minutes, under the same 
laboratory conditions. The sham healer did not have any 
knowledge about the Biofield Energy Treatment. After that, 
the Biofield Energy Treated and untreated samples were kept 
in similar sealed conditions and characterized thoroughly by 
PXRD, PSD, FT-IR, UV-visible spectroscopy, TGA, and 
DSC analysis.  
2.3. Characterization 
2.3.1. Powder X-ray Diffraction (PXRD) Analysis 
The PXRD analysis was performed on PANalytical X’pert 
Pro powder X-ray diffractometer system. The X-ray of 
wavelength 1.54056 Å was used. The data was collected in 
the form of a chart of the Bragg angle (2θ) vs. intensity, and a 
detailed table containing information on peak intensity 
counts, d value (Å), relative intensity (%), full width half 
maximum (FWHM) (θ°). From the XRD results, the 
crystallite size (G) was calculated using X’pert data collector 
and X’pert high score plus processing software. The 
crystallite size (G) was calculated from the Scherrer equation 
[46, 47]. The method was based on the width of the 
diffraction patterns obtained in the X-ray reflected crystalline 
region. The crystallite size (G) was calculated by using the 
following equation 1: 
G = kλ/(bCosθ)                            (1) 
Where, k is the equipment constant (0.5), λ is the X-ray 
wavelength (0.154 nm); b in radians is the full-width at half 
of the peaks and θ is the corresponding Bragg angle. 
Percent change in crystallite size (G) was calculated using 
the following equation 2: 
%	change	in	crystallite	size	 =
		
	
× 100  (2) 
Where GControl and GTreated are the crystallite size of the 
control and Biofield Energy Treated samples, respectively. 
A total of 500.18 mg of the control and Biofield Energy 
Treated samples individually were used for the analysis and 
prepared by the back loading technique using the sample 
preparation kit. The sample was spread on the holder ring in 
sufficient quantity to fill the ring cavity. It was then pressed 
down using a powder press block and scrapped the powder 
that was in surplus using a glass slide in order to get a 
densely packed specimen. The bottom plate was placed onto 
the holder ring and clamped in position. The sample holder 
was then removed from the sample preparation table by 
turning it upside down. A smooth surface of the sample was 
obtained to ensure optimum results. 
2.3.2. Particle Size Distribution (PSD) Analysis 
The average particle size and particle size distribution 
were analyzed using Malvern Mastersizer 2000, UK, with a 
detection range from 0.01 µm to 3000 µm. The sample unit 
was filled with dispersant medium and operated the stirrer at 
2500 rpm. Alignment of the optics was done and taken the 
background measurement. After the background 
measurement, the sample was added in to the sample unit 
with constant monitoring of the obscuration. When the 
obscuration of the sample reached in between 15% and 20%, 
further addition of the sample stopped. When the obscuration 
was stable, the measurement was taken twice and the average 
was taken of the two measurements. The average histogram 
of the two measurements was recorded. The printout of the 
average histogram of the two measurements were 
documented in this study. Along with histogram, the data 
was presented in a table format which includes particle size 
(µm). Also, the values at below 10% level (d10), 50% level 
(d50), and 90% level (d90) were calculated from the histogram, 
and the calculations such as surface area (m2/g) were done by 
using Mastersizer 2000 software. The percent change in 
particle size (d) for at below 10% level (d10), 50% level (d50), 
and 90% level (d90) was calculated using the following 
equation 3: 
%	change	in	particle	size =
##
#
× 100      (3) 
Where, dControl and dTreated are the particle size (µm) for at 
below 10% level (d10), 50% level (d50), and 90% level (d90) of 
the control and Biofield Energy Treated samples, 
respectively. 
The percent change in surface area (S) was calculated 
using the following equation 4: 
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%	change	in	surface	area =
&	&	
&	
× 100   (4) 
Where, SControl and STreated are the surface area of the 
control and Biofield Energy Treated samples, respectively. 
2.3.3. Fourier Transform Infrared (FT-IR) Spectroscopy 
FT-IR spectroscopy of the magnesium gluconate was 
performed using Spectrum Two (Perkin Elmer, USA) Fourier 
Transform Infrared Spectrometer with the frequency range of 
400-4000 cm-1 by using the pressed KBr disk technique. 
2.3.4. Ultraviolet-Visible Spectroscopy (UV-Vis) Analysis 
The UV-Vis spectral analysis was carried out using 
Shimadzu UV-2450 with UV Probe, Japan. The spectrum 
was recorded using 1 cm quartz cell with a slit width of 1.0 
nm. The wavelength range chosen for recording the spectra 
was 190-800 nm. The absorbance spectra (in the range of 0.2 
to 0.9) and absorbance maximum (λmax) were recorded. 
2.3.5. Thermal Gravimetric Analysis (TGA) 
The TGA analysis was performed using TGA Q50 (TA 
Instruments, USA) at a heating rate of 10ºC/min from room 
temperature i.e. 25°C to 900°C in a nitrogen atmosphere. A 
total of 15 mg of sample was weighed in a platinum crucible. 
In TGA, the weight loss for each step was recorded in grams 
as well as in percent loss with respect to the initial weight. 
Also, the onset, endset, and peak temperature for each step 
were recorded in TGA. In DTG, the onset, endset, peak 
temperature, integral area of the peak and change in heat 
(J/g) of each peak were recorded.  
Percent change in weight loss (W) was calculated using 
the following equation 5: 
%	change	in	weight	loss =
)	)	
)	
× 100      (5) 
Where WControl and WTreated are the weight loss of the 
control and Biofield Energy Treated samples, respectively. 
2.3.6. Differential Scanning Calorimetry (DSC) 
Analysis was performed using the DSC Q20 (TA 
Instruments, USA) Differential Scanning Calorimeter. A total 
of 8.23 mg of sample was weighed and sealed in an 
aluminum pan and equilibrated at 25°C and heated up to 
450°C at the heating rate of 10°C/min under nitrogen gas as 
purge atmosphere with the flow rate of 50 mL/min. The value 
for onset, endset, peak temperature, peak height (mJ or mW), 
peak area, and change in heat (J/g) for each peak were 
recorded. 
The percent change in melting point (T) was calculated 
using the following equation 6: 
%	change	in	melting	point =
++
+
× 100     (6) 
Where, TControl and TTreated are the melting point of the 
control and Biofield Energy Treated samples, respectively. 
The percent change in the latent heat of fusion (∆H) was 
calculated using the following equation 7: 
%	change	in	ΔH	fusion =
./0/
0/
× 100   (7) 
Where ∆HControl and ∆HTreated are the latent heat of fusion 
of the control and Biofield Energy Treated samples, 
respectively. 
3. Results and Discussion 
3.1. Powder X-ray Diffraction (PXRD) Analysis 
The PXRD diffractograms of both the control and Biofield 
Energy Treated magnesium gluconate, as shown in Figure 1, 
exhibited sharp and intense peaks indicating that both of the 
samples were crystalline in nature. PXRD data such as the 
Bragg angle (2θ), relative intensity (%), full width half 
maximum (FWHM) (θ°), and crystallite size (G) for the 
control and Biofield Energy Treated magnesium gluconate 
are presented in Table 1. The crystallite size was calculated 
using Scherrer equation [46, 47]. The highest intense peak in 
both the control and Biofield Energy Treated samples was 
observed at Bragg’s angle (2θ) equal to 5.06°. Table 1 
displays the changes of the relative intensities and crystallite 
size of the Biofield Energy Treated magnesium gluconate 
compared with the control sample, while their Bragg’s angle 
(2θ) were almost similar.  
The crystallite sizes at position 2θ equal to nearly 5.1°, 
18.5°, 19.0°, 23.6°, 25.5°, 27.4°, 29.3°, 31.4°, 34.5°, 35.7°, 
37.6°, 38.9°, 39.6°, and 40.4° (Table 1, entry 1, 6, 7, 11, 13-
16, and 18-23) were significantly increased from 11.09% to 
99.98% in the Biofield Energy Treated sample compared 
with the control sample. Consequently, the crystallite sizes of 
the Biofield Energy Treated sample at 2θ equal to nearly 
9.9°, 13.9°, 15.8°, 18.0°, 19.1°, 22.4°, 24.7°, 31.9°, and 49.3° 
(Table 1, entry 2-5, 8, 10, 12, 17, and 26) were significantly 
decreased from 14.26% to 24.96% compared with the control 
sample. 
Table 1. PXRD data for the control and Biofield Energy Treated magnesium gluconate. 
Entry No. 
Bragg angle (°2θ) Relative Intensity (%) FWHM (°2θ) Crystallite size (G, nm) 
Control Treated  Control Treated  Control Treated  Control Treated  % change* 
1 5.05 5.06 100.00 100.00 0.1004 0.0836 43.88 52.70 20.10 
2 9.89 9.88 39.51 35.25 0.0836 0.1004 52.85 44.00 -16.73 
3 13.89 13.88 44.40 45.28 0.1004 0.1171 44.16 37.86 -14.26 
4 15.82 15.82 30.24 26.18 0.1004 0.1338 44.26 33.21 -24.96 
5 17.92 17.99 57.74 45.76 0.1673 0.2175 26.63 20.49 -23.07 
6 18.49 18.46 88.91 83.51 0.1338 0.1171 33.33 38.08 14.26 
7 19.03 19.03 71.88 65.81 0.1673 0.1506 26.68 29.64 11.09 
8 19.15 19.14 53.76 52.24 0.0669 0.0836 66.72 53.39 -19.98 
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Entry No. 
Bragg angle (°2θ) Relative Intensity (%) FWHM (°2θ) Crystallite size (G, nm) 
Control Treated  Control Treated  Control Treated  Control Treated  % change* 
9 20.09 20.06 23.18 21.26 0.1171 0.1171 38.17 38.17 0.00 
10 22.37 22.38 55.23 51.03 0.1171 0.156 38.32 28.76 -24.93 
11 23.63 23.62 55.82 52.38 0.1338 0.1171 33.61 38.40 14.26 
12 24.71 24.72 23.35 23.04 0.1004 0.1171 44.88 38.48 -14.26 
13 25.46 25.50 18.90 17.51 0.1840 0.1338 24.53 33.73 37.53 
14 27.38 27.37 42.09 39.51 0.2175 0.1171 20.83 38.69 85.73 
15 29.31 29.31 36.73 34.74 0.1840 0.1004 24.73 45.32 83.27 
16 31.42 31.41 26.88 24.02 0.1004 0.0836 45.55 54.70 20.09 
17 31.86 31.87 23.61 22.45 0.1338 0.1673 34.22 27.37 -20.02 
18 34.51 34.52 23.62 22.28 0.1171 0.0836 39.37 55.14 40.08 
19 35.70 35.72 35.27 32.66 0.1673 0.1338 27.65 34.57 25.04 
20 37.61 37.60 27.95 25.47 0.1338 0.1004 34.76 46.32 33.26 
21 38.85 38.93 21.14 20.13 0.2007 0.1506 23.26 31.01 33.30 
22 39.64 39.61 21.18 34.05 0.3680 0.1840 12.72 25.43 99.98 
23 40.43 40.40 40.09 39.07 0.1506 0.1171 31.15 40.06 28.60 
24 41.87 41.75 21.35 20.42 0.3680 0.3680 12.81 12.81 -0.04 
25 44.12 44.14 28.49 25.62 0.1004 0.1004 47.32 47.32 0.01 
26 49.27 49.27 15.79 14.39 0.2007 0.2342 24.14 20.69 -14.30 
Average crystallite size 34.48 37.17 7.79 
FWHM: Full width half maximum, *denotes the percentage change in the crystallite size of the Biofield Energy Treated sample with respect to the control 
sample. 
 
Figure 1. X-ray diffractograms of the control and Biofield Energy Treated magnesium gluconate.  
Furthermore, the crystallite sizes of the control and 
Biofield Energy Treated magnesium gluconate hydrate at 2θ 
equal to nearly 20.1°, 41.9°, and 44.1° (Table 1, entry 9, 24, 
and 25) remained same. The average particle size of the 
Biofield Energy Treated sample was significantly increased 
by 7.79% compared to the control sample. Scientific 
literature reported that the changes in the XRD patterns, such 
as crystallite size and relative intensities, indicated the 
modification of the morphology of the crystal as well as the 
proof of polymorphic transition [48-50]. As the crystal 
morphology of the Biofield Energy Treated sample was 
altered compared with the control sample, the Biofield 
Energy Treated sample might be a new polymorphic form of 
magnesium gluconate. The crystal pattern, size and even 
polymorphic form of a pharmaceutical play important roles 
in drug solubility, dissolution and bioavailability. It has been 
reported in the literature that the alteration in crystal 
morphology has significant impact on the in vitro dissolution 
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rate, which is related with the bioavailability of orally 
administered pharmaceutical/nutraceutical [43]. So, it can be 
concluded that the Biofield Energy Healing Treatment might 
be a very useful method for enhancing the bioavailability of 
magnesium gluconate. 
3.2. Particle Size Distribution (PSD) Analysis 
The particle sizes at d10, d50, and d90 values and surface area of 
both the control and Biofield Energy Treated magnesium 
gluconate were investigated and the results are presented in 
Table 2. The control sample showed a particle size values of d10 
(6.567), d50 (40.582 µm), and d90 (173.282 µm). After the 
Biofield Energy Healing Treatment, the particle size values of 
magnesium gluconate were found to be 6.215, 35.976, and 
171.714 µm for d10, d50, and d90, respectively. Thus, the particle 
sizes at d10, d50 and d90 values of Biofield Energy Treated 
magnesium gluconate were decreased by 5.36%, 11.35% and 
0.90%, respectively compared with the control sample.  
Table 2. Particle size data (d10, d50, and d90) and surface area of the control and Biofield Energy Treated magnesium gluconate. 
Test Item d10 (µm) d50 (µm) d90 (µm) Surface area (m
2/g) 
Control  6.567 40.582 173.282 0.361 
Biofield Energy Treated 6.215 35.976 171.714 0.388 
Percent change* (%)  -5.36 -11.35 -0.90 7.48 
*denotes the percentage change in the particle size data (d10, d50, and d90) and surface area of the Biofield Energy Treated sample with respect to the control 
sample. 
The surface area analysis revealed that the surface area of the 
Biofield Energy Treated magnesium gluconate (0.361 m2/g) was 
significantly increased by 7.48% from the surface area of the 
control magnesium gluconate (0.388 m2/g) as shown in Table 2.  
Poorly crystallized compounds possess more surface area 
and higher exchange capacities than well-crystallized 
compounds [51]. In addition, the variation of the crystal 
morphology in the Biofield Energy Treated sample, which 
was well-supported from PXRD data, may cause to alter the 
surface area of the Biofield Energy Treated magnesium 
gluconate in comparison with the control sample. It has been 
well established that the particle size, shape and surface area 
of pharmaceutical compounds have an important impact on 
solubility, dissolution and in vivo bioavailability, as well as in 
helping the design of new drug delivery systems [52, 53]. 
Reducing particle size and higher surface area would enhance 
the solubility of the solid particles, and consequently would 
increase the dissolution rate and bioavailability [54]. Thus, it 
is assumed that the Biofield Energy Treated magnesium 
gluconate might be dissolved and absorbed at a faster rate 
and may possibly have more bioavailability than normal 
magnesium gluconate. 
 
Figure 2. FT-IR spectra of the control and Biofield Energy Treated magnesium gluconate. 
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3.3. Fourier Transform Infrared (FT-IR) Spectroscopy 
The FT-IR spectra of both the control and Biofield Energy 
Treated magnesium gluconate, as shown in Figure 2, 
exhibited only one broad band with high intensity at 3398 
cm-1, which was attributed to the stretching vibrations of the 
hydroxyl groups originating from the water present in the 
magnesium gluconate hydrate. The bands of stretching 
vibrations of primary and secondary hydroxyl groups from 
the gluconate part of the compound appeared in this region. 
These bands were remained invisible due to the intensive 
broad band of water [55].  
The absorption peaks for the deformation vibration of the 
hydroxyl groups in the plane δ(OH) and out-of-plane γ(OH) 
indicating the presence of primary and secondary hydroxyl 
groups were observed at 1434 cm-1, 636 cm-1, and 583 cm-1 
in the spectrum of the control sample. However, the vibration 
bands for the of primary and secondary hydroxyl groups 
were found in the spectra of the Biofield Energy Treated 
magnesium gluconate at 1434 cm-1, 636 cm-1, and 581 cm-1. 
The FT-IR spectra of the control sample displayed C-H 
stretching at 2936 cm-1 and 1381 cm-1, while these peaks 
were observed in the Biofield Energy Treated sample at 2935 
cm-1 and 1381 cm-1. A very sharp and intensive band at 1605 
cm-1 for C=O stretching vibration of a carbonyl group of 
carboxylate anion was observed in the spectrum of the 
control sample, while this vibration band was found in the 
spectrum of the Biofield Energy Treated magnesium 
gluconate at 1606 cm-1. The band of the C-O stretching 
vibrations of the primary alcohol group was observed in the 
spectra of the control and Biofield Energy Treated samples at 
1056 cm-1 and 1057 cm-1, respectively. The absorption peaks 
at 1231 cm-1 and 1142 cm-1 due to the C-O stretching 
vibrations of the secondary alcohol groups were observed in 
the spectra of both the control and Biofield Energy Treated 
samples. The FT-IR analysis indicated that there was no 
significant alteration of the characteristic peaks for the 
functional groups. Hence, it can be concluded that the 
structure of the magnesium gluconate remained the same in 
both the Biofield Energy Treated and control samples.  
3.4. Ultra Violet-Visible Spectroscopy (UV-Vis) Analysis 
Literature reported that 0.1% aqueous solution of 
magnesium gluconate showed a maximum absorption peak 
(λmax) at 194.7 nm [56]. The UV-vis spectra of both the 
control and Biofield Energy Treated samples (Figure 3) 
showed that the wavelength for the maximum absorbance 
(λmax) of both the control and Biofield Energy Treated 
samples were at 198.8 nm with a minor shift of absorbance 
maxima from 2.3126 (control sample) to 2.3154 (Biofield 
Energy Treated sample). 
 
 
Figure 3. UV-Vis spectra of the control and Biofield Energy Treated magnesium gluconate. 
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The UV absorbance happens due to the different types of 
energy transitions from the singlet to the singlet excited state 
such as σ→σ*, n→π*, and π →π*. These types of electronic 
transitions are happened when the difference in energy 
between the lowest unoccupied molecular orbital (LUMO) 
and the highest occupied molecular orbital (HOMO) is 
significantly higher than the activation energy of the 
compound [57]. As there was no significant change in the 
λmax of the Biofield Energy Treated sample compared with 
the control, it is inferred that the structural configuration or 
activation energy of the Biofield Energy Treated sample was 
not different from the control sample. 
3.5. Thermal Gravimetric Analysis (TGA) 
The TGA and DSC are very useful techniques for the 
comparison of the thermal stabilities of pharmaceutical 
solids, determination of several kinetic parameters, and 
accomplishment of drug/excipient compatibility data for the 
pre-formulation study [58]. The TGA study of both the 
control and the Biofield Energy Treated magnesium 
gluconate (Figure 4) exhibited four thermal degradation steps 
and the data are presented in Table 3.  
Table 3. Thermal degradation steps of the control and Biofield Energy Treated magnesium gluconate. 
S. No. 
Temperature (°C) % Weight loss % Change* 
Control Biofield Energy Treated Control Biofield Energy Treated  
1st step of degradation 75.49 73.00 1.11 1.09 -1.80 
2nd step of degradation 188.00 187.37 8.76 8.62 -1.60 
3rd step of degradation 299.88 300.51 38.16 38.50 0.89 
4th step of degradation 600.84 597.63 21.40 21.30 -0.47 
Total weight loss - - 69.43 69.51 0.12 
*denotes the percentage change in the weight loss of the Biofield Energy Treated sample with respect to the control sample. 
The weight losses of the Biofield Energy Treated sample at 
the first, second, and fourth steps of thermal degradation 
were reduced by 1.80%, 1.60% and 0.47%, respectively 
compared with the control sample. Consequently, the weight 
loss of the Biofield Energy Treated magnesium gluconate at 
the third step degradation was increased by 0.89% compared 
with the control sample. The first step degradation was 
probably associated with the removal of water of both the 
samples.  
 
Figure 4. TGA thermograms of both the control and Biofield Energy Treated magnesium gluconate. 
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The total weight loss was 69.43% and 69.51% in the 
control and Biofield Energy Treated samples, respectively 
from their initial weight from room temperature to 600°C 
(Table 3). Thus, the total weight loss of the Biofield Energy 
Treated sample was increased by 0.12% compared with the 
control sample.  
3.6. Differential Scanning Calorimetry (DSC) Analysis 
The DSC thermograms of both the control and Biofield 
Energy Treated magnesium gluconate (Figure 5) and showed 
two endothermic peaks. Their DSC data are presented in 
Table 4. The first broaden endothermic (minor) peak was due 
to the water removal from the sample. The second sharp 
endothermic (major) peak was due to the melting temperature 
of the magnesium gluconate.  
The DSC data analysis (Table 4) revealed that the melting 
temperature of the Biofield Energy Treated sample 
(171.29°C) was increased by 0.18% compared with the 
control sample (170.99°C). The control and Biofield Energy 
Treated samples of magnesium gluconate exhibited a latent 
heat of fusion of 346.70 J/g and 272.80 J/g, respectively. The 
latent heat of fusion in the Biofield Energy Treated 
magnesium gluconate was significantly increased by 27.09% 
compared with the control sample (Table 4). 
 
Figure 5. DSC thermograms of the control and Biofield Energy Treated magnesium gluconate. 
Table 4. The latent heat of fusion (J/G) and melting point (°C) values of the control and Biofield Energy Treated magnesium gluconate. 
Endothermic peak Description Tonset (°C) Tpeak (°C) Tendset (°C)  ∆Hfusion (J/g) 
 Control sample 64.28 83.42 100.47 18.42 
Minor peak Biofield Energy Treated sample 68.38 86.01 99.17 17.82 
 % Change* 6.38 3.10 -1.29 -3.26 
 Control sample 158.04 170.99 200.00 272.80 
Major peak Biofield Energy Treated sample 158.76 171.29 200.00 346.70 
 % Change* 0.46 0.18 0.00 27.09 
Tonset:
 Onset melting temperature, Tpeak: Peak melting temperature, Tendset: Endset melting temperature, ∆H: Latent heat of fusion, 
*denotes the percentage 
change of the Biofield Energy Treated sample with respect to the control sample. 
Additionally, the temperature for water removal from the 
Biofield Energy Treated sample was increased by 3.10% with 
a 3.26% decreased ∆Hfusion compared with the control 
sample. The analysis indicated that the thermal stability of 
the Biofield Energy Treated sample was significantly 
improved compared with the control sample.  
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4. Conclusions 
The current analysis anticipated the significant impact of 
The Trivedi Effect® - Energy of Consciousness Healing 
Treatment (Biofield Energy Healing Treatment) on 
physicochemical, thermal and behavioral properties of 
magnesium gluconate. The PXRD analysis showed that the 
crystallite size of The Trivedi Effect® Treated magnesium 
gluconate was significantly altered from -24.96% to 99.98% 
compared with the control sample. The average crystallite 
size of the Biofield Energy Treated sample was significantly 
increased by 7.79% compared with the control sample. 
Overall, the PXRD analysis exposed that the crystal 
morphology of the Biofield Energy Treated sample was 
significantly changed compared with the control sample. 
PSD analysis revealed that the particle sizes at d10, d50 and d90 
values were decreased by 5.36%, 11.35% and 0.90%, 
respectively in The Trivedi Effect® Treated sample compared 
with the control sample. Consequently, the surface area of the 
Biofield Energy Treated sample was significantly increased 
by 7.48% compared with the control sample. The TGA 
analysis showed four steps thermal degradation of both the 
samples and the total weight loss was increased by 0.12% in 
the Biofield Energy Treated sample compared with the 
control sample. The DSC analysis demonstrated that the 
melting temperature of the Biofield Energy Treated sample 
(171.29°C) was increased by 0.18% with a significant 
(27.09%) enhancement in the latent heat of fusion compared 
with the control sample (170.99°C). This finding revealed 
that the thermal stability of the Biofield Energy Treated 
sample was significantly improved compared with the 
control sample. Thus, The Trivedi Effect® Treated 
magnesium gluconate would be a new polymorphic form of 
magnesium gluconate, which would be more soluble, 
bioavailable, and thermally stable compared with the 
untreated compound. The Biofield Energy Treated sample 
could be more stable during manufacturing, delivery or 
storage conditions than the untreated sample. Briefly, The 
Trivedi Effect® - Energy of Consciousness Healing 
Treatment (Biofield Energy Healing Treatment) could be a 
useful approach in the design of better nutraceutical and/or 
pharmaceutical formulations that can offer significant 
therapeutic responses against various diseases such as 
diabetes mellitus, allergies and septic shock; stress-related 
disorders like sleep disorder, insomnia, anxiety, depression, 
Attention Deficit Disorder (ADD), Attention Deficit 
Hyperactive Disorder (ADHD), mental restlessness (mind 
chattering), brain frog, low libido, impotency, lack of 
motivation, mood swings, fear of the future, confusion, 
migraines, headaches, forgetfulness, overwhelm, loneliness, 
worthlessness, indecisiveness, frustration, irritability, chronic 
fatigue, obsessive/compulsive behavior and panic attacks; 
inflammatory diseases and immunological disorders like 
Lupus, Systemic Lupus Erythematosus, Hashimoto 
Thyroiditis, Type 1 Diabetes, Asthma, Chronic peptic ulcers, 
Tuberculosis, Hepatitis, Chronic active hepatitis, Celiac 
Disease (gluten-sensitive enteropathy), Addison Disease, 
Crohn's disease, Graves’ Disease, Pernicious and Aplastic 
Anemia, Sjogren Syndrome, Irritable Bowel Syndrome 
(IBS), Multiple Sclerosis, Rheumatoid arthritis, Chronic 
periodontitis, Ulcerative colitis, Chronic sinusitis, 
Myasthenia Gravis, Atherosclerosis, Vasculitis, Dermatitis, 
Diverticulitis, Rheumatoid Arthritis, Reactive Arthritis, 
Alopecia Areata, Psoriasis, Scleroderma, Fibromyalgia, 
Chronic Fatigue Syndrome and Vitiligo; aging-related 
diseases like cardiovascular disease, arthritis, cancer, 
Alzheimer’s disease, dementia, cataracts, osteoporosis, 
diabetes, hypertension, glaucoma, hearing loss, Parkinson’s 
Disease, Huntington’s Disease, Prion Disease, Motor 
Neurone Disease, Spinocerebellar Ataxia, Spinal muscular 
atrophy, Amyotrophic lateral sclerosis, Friedreich’s Ataxia 
and Lewy Body Disease, chronic infections and much more. 
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